Abstract
Fetal lung adenocarcinoma (FLAC) is a rare variant of lung adenocarcinoma. Studies regarding FLAC have been based only on histopathological observations, thus representative in vitro models of FLAC cultures are unavailable. We have established and characterized a human primary FLAC cell culture, exploring its biology, chemosensitivity, and migration. FLAC cells and specimen showed significant upregulation of VEGF165 and HIF-1α mRNA levels. This observation was confirmed by in vitro chemosensitivity and migration assay, showing that only Axitinib was comparable to Cisplatin treatment. We provide a suitable in vitro model to further investigate the nature of this rare type of cancer.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenocarcinoma / diagnostic imaging
-
Adenocarcinoma / genetics
-
Adenocarcinoma / metabolism
-
Adenocarcinoma / pathology*
-
Adenocarcinoma of Lung
-
Aged, 80 and over
-
Antineoplastic Agents / pharmacology*
-
Axitinib
-
Cell Movement / drug effects*
-
Cell Survival / drug effects
-
Cisplatin / pharmacology
-
Female
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Hypoxia-Inducible Factor 1, alpha Subunit / genetics
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Imidazoles / pharmacology*
-
Indazoles / pharmacology*
-
Lung Neoplasms / diagnostic imaging
-
Lung Neoplasms / genetics
-
Lung Neoplasms / metabolism
-
Lung Neoplasms / pathology*
-
Middle Aged
-
Neoplasm Invasiveness
-
Protein Kinase Inhibitors / pharmacology*
-
RNA, Messenger / metabolism
-
Radiography
-
Tumor Cells, Cultured
-
Up-Regulation
-
Vascular Endothelial Growth Factor A / genetics
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Antineoplastic Agents
-
HIF1A protein, human
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Imidazoles
-
Indazoles
-
Protein Kinase Inhibitors
-
RNA, Messenger
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Axitinib
-
Cisplatin